NCT00045188View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

July 31, 2004

Conditions
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

imatinib mesylate

Given PO

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00045188 - Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter